梯瓦上藥攜手戰(zhàn)略合作，共同呵護(hù)“安穩(wěn)人生”

來源：百濟(jì)藥房藥訊 2020-07-22

7月21日，梯瓦制藥工業(yè)有限公司與上藥控股有限公司簽署戰(zhàn)略合作協(xié)議，上藥控股將為梯瓦在中國上市的創(chuàng)新藥“氘丁苯那嗪片（安泰坦®Austedo®）”提供保稅進(jìn)口、政府事務(wù)、市場準(zhǔn)入、全國分銷等一站式服務(wù)，更好地為人民健康事業(yè)服務(wù)。

On July 21st , Mr. Larry Merizalde, the general manager of Greater China of Teva Pharmaceutical Industries Co., Ltd. has signed a strategic collaboration agreement with Mr. Yongzhong Li, the executive director and vice president of Shanghai Pharmaceuticals Holding Co., Ltd., and the general manager of Shanghai Pharmaceutical Co., Ltd.,. Shaphar will provide Teva with bonded import, government affairs, market access, national distribution and other one-stop services for the innovative drug “Deutetrabenazine Tablet (Austedo®) which was firstly listed in China in order to offer the better services to people’s health.

由于全球疫情的影響，本次簽約采用線上線下結(jié)合的創(chuàng)新方式，不僅在線上匯集了來自中國香港、泰國以及以色列的Teva伙伴們，梯瓦大中華區(qū)總經(jīng)理Larry Merizalde與在現(xiàn)場參會的上海醫(yī)藥執(zhí)行董事、副總裁，上藥控股總經(jīng)理李永忠更是通過科技創(chuàng)新手段同時在戰(zhàn)略簽約板上簽名，讓分布在全球的伙伴們共同見證！

It is worth to be mentioned that because of the impact of the global epidemic, the signing ceremony adopted the new-tech way with online and offline combination, and set the online connection with partners from Hong Kong, Thailand, and Israel. Moreover, Larry Merizalde, was attending the meeting in Hongkong, and Mr. Yongzhong Li, was present at the meeting in Shanghai, signed their names on the strategic signing board through innovative technological way in order to be witnessed by partners around the world.It is worth to be mentioned that because of the impact of the global epidemic, the signing ceremony adopted the new-tech way with online and offline combination, and set the online connection with partners from Hong Kong, Thailand, and Israel. Moreover, Larry Merizalde, was attending the meeting in Hongkong, and Mr. Yongzhong Li, was present at the meeting in Shanghai, signed their names on the strategic signing board through innovative technological way in order to be witnessed by partners around the world.

上藥控股助理總經(jīng)理、上藥國際供應(yīng)鏈總經(jīng)理宋潞潞表示，非常榮幸可以現(xiàn)場見證梯瓦與上藥控股的戰(zhàn)略合作，也對梯瓦的支持與信任表示衷心的感謝。上藥控股從一個區(qū)域性公司發(fā)展成為目前中國最大的醫(yī)藥商業(yè)公司之一，秉承“服務(wù)為榮”的經(jīng)營理念，得到了眾多像梯瓦一樣全球領(lǐng)先的制藥企業(yè)的認(rèn)可。同時，在未來，全新的進(jìn)口平臺—上藥國際供應(yīng)鏈有限公司也將依靠臨港自由貿(mào)易區(qū)的優(yōu)惠政策，整合全球資源配置，爭取為梯瓦提供更便利、更優(yōu)質(zhì)的服務(wù)。

Mrs. Lulu Song, the associated general manager of Shaphar, the general manager of SPLG, claimed that it was a great honor to witness the strategic cooperation between Teva and Shaphar and expressed thanks to Teva for the support and trust. Shaphar has grown from a regional company, into one of the largest pharmaceutical commercial companies in China. By adhering to the business philosophy of "to be service-oriented", Shaphar has received recognition by many leading pharmaceutical companies in the world like Teva. In addition, in the future, the new import platform -- Shanghai Pharmaceutical Lin-gang Special Area Co., Ltd. will also rely on the preferential policies of Lin-gang Free Trade Zone, integrating global resources allocation, and keeping on providing Teva with more convenient and satisfactory services.

作為治療與亨廷頓病有關(guān)的舞蹈病和成人遲發(fā)性運動障礙的有效藥物，依托對罕見病有益的國家政策，安泰坦®Austedo®將會為更多的中國患者帶來福音。同時，上海醫(yī)藥作為中國最大的藥品進(jìn)口分銷平臺，相信在未來一定可以與梯瓦共同努力，推動中國醫(yī)療事業(yè)的蓬勃發(fā)展。

As the effective treatment for chorea associated with Huntington's disease (HD) and Tardive Dyskinesia (TD) in adults, Austedo® will benefit more patients in China based on the beneficial national policy for rare diseases. At the same time, as the largest pharmaceutical import and distribution platform in China, Shaphar will make joint efforts with Teva to promote the vigorous development of China's medical industry.

背

景

介

紹

Background Information

關(guān)于亨廷頓有關(guān)的舞蹈病

亨廷頓?。℉D）是一種罕見的致命的神經(jīng)退化性疾病，亞洲每十萬人中大約有0.4人患病，平均發(fā)病年齡為40歲。舞蹈?。o意識的、隨機(jī)和突然的扭動和/或轉(zhuǎn)動）是這種疾病最為顯著的表現(xiàn)之一，發(fā)生在大約90%的病人當(dāng)中。

About chorea associated with Huntington's disease (HD)

Huntington's disease is a rare but fatal neurodegenerative disease, affecting about 0.4 per 100,000 people in Asia, with an average age of 40 years. Chorea (involuntary, random and sudden twists and/or turns) is one of the most prominent signs of the disease and occurs in approximately 90% of patients.

關(guān)于成人遲發(fā)性運動障礙

遲發(fā)性運動障礙（TD）是一種使人衰弱的運動紊亂，以舌頭、嘴唇、臉、軀體和四肢部位的重復(fù)且不可控的運動為特征。TD在長期接受抗精神病藥治療的中國的精神分裂癥患者當(dāng)中的患病率為33.7%，可能是由某些用于治療精神健康狀況的藥物引起的，這意味著使用這些藥物的精神分裂癥患者中有三分之一可能患有TD。

About Tardive Dyskinesia (TD) in adults

Tardive Dyskinesia is a debilitating movement disorder characterized by repetitive and uncontrollable movements of the tongue, lips, face, body, and limbs. TD has a prevalence of 33.7% among Chinese schizophrenia patients receiving long-term antipsychotic treatment and may be caused by certain drugs used to treat mental health conditions, meaning that one-third of schizophrenics using these drugs may have TD.

關(guān)于梯瓦制藥

梯瓦是一家全球性的醫(yī)藥公司，也是全球最大的仿制藥公司，成立于1901年。同時，致力于成為全球仿制藥和生物制藥的領(lǐng)導(dǎo)者，開發(fā)及生產(chǎn)優(yōu)質(zhì)仿制藥、創(chuàng)新的?？扑幬锛八幬锘钚猿煞郑蕴岣吆透纳撇』嫉纳钯|(zhì)量。

About Teva

Founded in 1901, Teva is a global pharmaceutical company, as well as the largest generic drug company in the world. Meanwhile, Teva is committed to being a global leader in generic drugs and biopharmaceuticals, developing and producing quality generic drugs, innovative specialty drugs and active ingredients to improve living quality of patients.

關(guān)于安泰坦®

安泰坦®是梯瓦創(chuàng)新研發(fā)的原研藥，于2017年4月獲得美國FDA批準(zhǔn)，是FDA首次批準(zhǔn)的氘代產(chǎn)品，也是針對與亨廷頓病有關(guān)的舞蹈病的歷史上第二個藥物；在美國的獲批適應(yīng)癥包括與亨廷頓?。℉D）有關(guān)的舞蹈病以及成人遲發(fā)性運動障礙（TD）。其中TD適應(yīng)癥被批準(zhǔn)為突破性治療。FDA對安泰坦®的批準(zhǔn)代表了HD患者的一個重要的新治療選擇。

About Austedo®

Austedo®, a drug innovatively developed by Teva, was approved by FDA in April 2017. It is the first FDA approved deuterium product and the second drug in the history related to chorea associated with Huntington's disease (HD). Approved indications in the United States include Chorea associated with Huntington's disease (HD) and Tardive Dyskinesia (TD) in adults. The TD indication was approved as a breakthrough therapy. FDA approval of Austedo® represents an important new treatment option for HD patients.

【溫馨提示】本網(wǎng)站內(nèi)容僅供參考，一切診斷和治療請遵從醫(yī)生的指導(dǎo)。

● 如果您有任何疑問，請聯(lián)系我們。
● 如需咨詢藥物，請點擊【服務(wù)指南】，了解相關(guān)信息。